You are here: Industry Insights > B.1.1.7

News List

Novavax’ COVID-19 vaccine almost 90 percent effective in Phase III trials europeanpharmaceuticalreview
July 02, 2021
In UK trials where 60 percent of COVID-19 cases were caused by the Alpha SARS-CoV-2 variant, the NVX-CoV2373 COVID-19 vaccine was 89.7 percent effective.
Monoclonal antibodies against COVID-19 have high potential, but efficacy against emerging variants muddled: GlobalData expresspharma
April 23, 2021
The prevalence of more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy.
B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest worldpharmanews
April 14, 2021
Two new studies, published in The Lancet Infectious Diseases and The Lancet Public Health, found no evidence that people with the B.1.1.7. variant experience worse symptoms or a heightened risk of developing long COVID compared with those infected ...
B.1.1.7 variant of COVID-19 spreading rapidly in United States worldpharmanews
April 02, 2021
The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from ...
Variant B.1.1.7 of COVID-19 associated with a significantly higher mortality rate worldpharmanews
March 15, 2021
The highly infectious variant of COVID-19 discovered in Kent, which swept across the UK last year before spreading worldwide, is between 30 and 100 per cent more deadly than previous strains, new analysis has shown.
Pfizer, BioNTech Study Shows COVID-19 Vaccine Elicits Antibodies that Neutralize New U.K. Strain americanpharmaceuticalreview
January 22, 2021
Pfizer and BioNTech announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known ...
ImmunityBio Simulations give clue to why South African strain of SARS-CoV-2 is rapidly spreading expresspharma
January 20, 2021
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2.
South African variant of SARS-CoV-2 should be more focus from governments: GobalData expresspharma
January 20, 2021
The South African variant shows more spike protein mutations than the UK variant, which might allow the virus to escape the immune protection provided by vaccination or prior infection.